Literature DB >> 9343306

3,5-Diiodo-L-thyronine (T2) has selective thyromimetic effects in vivo and in vitro.

S G Ball1, J Sokolov, W W Chin.   

Abstract

Recent data have suggested that the iodothyronine, 3,5-diiodo-l-thyronine (T2), has selective thyromimetic activity. In vivo, T2 has been shown to suppress TSH levels at doses that do not produce significant peripheral manifestations of thyroid hormone activity. Furthermore, T2 has been shown to produce smaller increments in peripheral indices of thyroid status than does T3, when doses resulting in equivalent suppression of circulating TSH are compared. We have assessed the selective thyromimetic activity of T2 in vivo and in vitro, and performed in vitro studies to assess the potential molecular basis for these selective properties. T2 was 100-fold less potent than T3 in stimulating GH mRNA levels in GH3 cells. In contrast, the iodothyronines were almost equivalent in their ability to downregulate TRbeta2 mRNA levels in this cell line. Both 3,3'-diiodo-L-thyronine and thyronine exhibited no significant thyromimetic effects on either process. In vivo, doses of T2 and T3 that were equivalent in their induction of hepatic malic enzyme (ME) mRNA did not produce equivalent suppression of circulating TSH, with T2 being only 27% as effective as T3. T2 was up to 500-fold less potent than T3 in displacing [125I]-T3 from in vitro translated specific nuclear receptors (TRs) and GH3 cell nuclear extracts. Electrophoretic mobility shift assays, assessing the ability of T2 to produce dissociation of TRbeta1 homodimers from inverted palindrome T3 response elements, indicated that T2 was also 1000-fold less potent than T3 in this respect. These data confirm that T2 has significant thyromimetic activity, and that this activity is selective both in vivo and in vitro. However, there are no data to support a selective central effect, T2 being relatively more potent in stimulating hepatic ME mRNA than in suppression of TSH in vivo. The basis for this differential thyromimetic activity is not selective affinity of the different TR isoforms for T2, or divergent properties of T2 in competitive binding and functional assays in vitro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343306     DOI: 10.1677/jme.0.0190137

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  32 in total

1.  Analysis of thyroid hormones in serum by liquid chromatography-tandem mass spectrometry.

Authors:  Dongli Wang; Heather M Stapleton
Journal:  Anal Bioanal Chem       Date:  2010-05-01       Impact factor: 4.142

Review 2.  Control of energy metabolism by iodothyronines.

Authors:  A Lanni; M Moreno; A Lombardi; P de Lange; F Goglia
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

3.  3,5-diiodo-L-thyronine increases FoF1-ATP synthase activity and cardiolipin level in liver mitochondria of hypothyroid rats.

Authors:  Alessandro Cavallo; Antonio Gnoni; Elena Conte; Luisa Siculella; Franco Zanotti; Sergio Papa; Gabriele Vincenzo Gnoni
Journal:  J Bioenerg Biomembr       Date:  2011-07-08       Impact factor: 2.945

4.  3,5-diiodo-L-thyronine (t2) in dietary supplements: what are the physiological effects?

Authors:  Arturo Hernandez
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

5.  Structural insights into thyroid hormone transport mechanisms of the L-type amino acid transporter 2.

Authors:  Katrin M Hinz; Katja Meyer; Anita Kinne; Ralf Schülein; Josef Köhrle; Gerd Krause
Journal:  Mol Endocrinol       Date:  2015-05-06

6.  Levothyroxine enhances glucose clearance and blunts the onset of experimental type 1 diabetes mellitus in mice.

Authors:  Livia López-Noriega; Nadia Cobo-Vuilleumier; Álvaro Jesús Narbona-Pérez; Juan Luis Araujo-Garrido; Petra Isabel Lorenzo; José Manuel Mellado-Gil; José Carlos Moreno; Benoit R Gauthier; Alejandro Martín-Montalvo
Journal:  Br J Pharmacol       Date:  2017-09-20       Impact factor: 8.739

Review 7.  Thyroid hormone analogues and derivatives: Actions in fatty liver.

Authors:  Maria Coppola; Daniela Glinni; Maria Moreno; Federica Cioffi; Elena Silvestri; Fernando Goglia
Journal:  World J Hepatol       Date:  2014-03-27

8.  Detection and quantification of 3,5,3'-triiodothyronine and 3,3',5'-triiodothyronine by electrospray ionization tandem mass spectrometry.

Authors:  Yuntao Zhang; Abigail H Conrad; Gary W Conrad
Journal:  J Am Soc Mass Spectrom       Date:  2005-09-22       Impact factor: 3.109

9.  Translating pharmacological findings from hypothyroid rodents to euthyroid humans: is there a functional role of endogenous 3,5-T2?

Authors:  Maik Pietzner; Ina Lehmphul; Nele Friedrich; Claudia Schurmann; Till Ittermann; Marcus Dörr; Matthias Nauck; René Laqua; Uwe Völker; Georg Brabant; Henry Völzke; Josef Köhrle; Georg Homuth; Henri Wallaschofski
Journal:  Thyroid       Date:  2014-11-24       Impact factor: 6.568

10.  Involvement of the L-Type Amino Acid Transporter Lat2 in the Transport of 3,3'-Diiodothyronine across the Plasma Membrane.

Authors:  Anita Kinne; Melanie Wittner; Eva K Wirth; Katrin M Hinz; Ralf Schülein; Josef Köhrle; Gerd Krause
Journal:  Eur Thyroid J       Date:  2015-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.